A Case of Rapidly Progressing Urothelial Carcinoma Arising After Living Donor Kidney Transplantation Treated with Chemotherapy and Immune Checkpoint Inhibitors.

IF 0.6 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Yonago acta medica Pub Date : 2025-02-15 eCollection Date: 2025-02-01 DOI:10.33160/yam.2025.02.009
Katsuya Hikita, Ryoma Nishikawa, Sosuke Taniguchi, Yukari Mae, Takuji Iyama, Tomoaki Takata, Shuichi Morizane, Masashi Honda, Atsushi Takenaka
{"title":"A Case of Rapidly Progressing Urothelial Carcinoma Arising After Living Donor Kidney Transplantation Treated with Chemotherapy and Immune Checkpoint Inhibitors.","authors":"Katsuya Hikita, Ryoma Nishikawa, Sosuke Taniguchi, Yukari Mae, Takuji Iyama, Tomoaki Takata, Shuichi Morizane, Masashi Honda, Atsushi Takenaka","doi":"10.33160/yam.2025.02.009","DOIUrl":null,"url":null,"abstract":"<p><p>The incidence of malignancy following long-term immunosuppression is increased in organ transplant recipients. We report a case of a patient with right ureteral and bladder cancer after living donor kidney transplantation for chronic glomerulonephritis and who was administered chemotherapy and immune checkpoint inhibitors. A 75-year-old male, 20 years post-living donor kidney transplantation for chronic glomerulonephritis, presented with malignant cells in urinary cytology. Despite initial treatments including transurethral resection of the bladder tumor, the tumor progressed to high-grade urothelial carcinoma. Computerized tomography results showed a right ureteral tumor and multiple lymph node metastases. Therefore, the patient underwent systemic chemotherapy with four cycles of gemcitabine and carboplatin. Pembrolizumab was administered due to rapid cancer progression; however, the cancer progressed further, and the patient was treated palliatively. The patient was treated with an immune checkpoint inhibitor with a reduced dose of immunosuppressive drugs with no rejection during the treatment course.</p>","PeriodicalId":23795,"journal":{"name":"Yonago acta medica","volume":"68 1","pages":"75-78"},"PeriodicalIF":0.6000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831043/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yonago acta medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33160/yam.2025.02.009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The incidence of malignancy following long-term immunosuppression is increased in organ transplant recipients. We report a case of a patient with right ureteral and bladder cancer after living donor kidney transplantation for chronic glomerulonephritis and who was administered chemotherapy and immune checkpoint inhibitors. A 75-year-old male, 20 years post-living donor kidney transplantation for chronic glomerulonephritis, presented with malignant cells in urinary cytology. Despite initial treatments including transurethral resection of the bladder tumor, the tumor progressed to high-grade urothelial carcinoma. Computerized tomography results showed a right ureteral tumor and multiple lymph node metastases. Therefore, the patient underwent systemic chemotherapy with four cycles of gemcitabine and carboplatin. Pembrolizumab was administered due to rapid cancer progression; however, the cancer progressed further, and the patient was treated palliatively. The patient was treated with an immune checkpoint inhibitor with a reduced dose of immunosuppressive drugs with no rejection during the treatment course.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
化疗和免疫检查点抑制剂治疗活体肾移植后发生进展迅速的尿路上皮癌1例。
器官移植受者长期免疫抑制后恶性肿瘤的发生率增高。我们报告一例慢性肾小球肾炎活体肾移植后右输尿管和膀胱癌患者,并给予化疗和免疫检查点抑制剂。75岁男性,慢性肾小球肾炎活体肾移植后20年,尿细胞学检查显示有恶性细胞。尽管最初的治疗包括经尿道膀胱肿瘤切除术,但肿瘤进展为高级别尿路上皮癌。计算机断层扫描结果显示右侧输尿管肿瘤及多发淋巴结转移。因此,患者接受了4个周期的吉西他滨和卡铂的全身化疗。由于癌症进展迅速,给予Pembrolizumab;然而,癌症进一步发展,病人接受了姑息治疗。患者在治疗过程中使用免疫检查点抑制剂和减少剂量的免疫抑制药物治疗,无排斥反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Yonago acta medica
Yonago acta medica MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.60
自引率
0.00%
发文量
36
审稿时长
>12 weeks
期刊介绍: Yonago Acta Medica (YAM) is an electronic journal specializing in medical sciences, published by Tottori University Medical Press, 86 Nishi-cho, Yonago 683-8503, Japan. The subject areas cover the following: molecular/cell biology; biochemistry; basic medicine; clinical medicine; veterinary medicine; clinical nutrition and food sciences; medical engineering; nursing sciences; laboratory medicine; clinical psychology; medical education. Basically, contributors are limited to members of Tottori University and Tottori University Hospital. Researchers outside the above-mentioned university community may also submit papers on the recommendation of a professor, an associate professor, or a junior associate professor at this university community. Articles are classified into four categories: review articles, original articles, patient reports, and short communications.
期刊最新文献
Longitudinal Dynamics of Soluble NKG2D Ligands in Mild and Moderate Coronavirus Disease-2019. Association of Labor Epidural Analgesia with Neonatal Umbilical Arterial Blood pH and Apgar Score: The Japan Environment and Children's Study (JECS). Next-Generation Artificial Intelligence for ADME Prediction in Drug Discovery: From Small Molecules to Biologics. Factors Affecting the Device Life of Voice Prosthesis in Laryngectomized Patients. Clinical Study of Complications Associated with Mandibular Reconstruction Plates Used in Resection of Oral Squamous Cell Carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1